In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

The novel drug reduces the need for burdensome phlebotomy and also addresses fatigue, thereby improving quality of life for ...

Daratumumab enhances treatment efficacy in newly diagnosed multiple myeloma, showing improved MRD negativity and ...

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

Rusfertide could be a new treatment option for patients with polycythemia vera, according to Andrew Kuykendall, MD.

Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, ...

CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

Zejula with Zytiga and prednisone delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer ...

By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet ...

Post hoc results support the initiation of SGLT2 inhibitors in patients with diabetic nephropathy regardless of iron deficiency. Canagliflozin treatment may improve iron markers and hemoglobin levels ...